社区成人长期使用质子泵抑制剂的处方精简

doi:10.3969/j.issn.1004-583X.2021.06.015

摘要/Abstract

摘要：

质子泵抑制剂(proton pump inhibitor,PPI)广泛应用于酸相关疾病,全球使用量明显增加,过度使用问题突出。近年来长期使用PPI引发全身多种不良事件的报道增多,其潜在不合理用药问题和全身各器官的潜在疾病风险逐渐受到关注。因此为了减少长期使用的潜在风险、减轻经济负担,开展PPI处方精简有重要意义。本文就PPI长期使用指征、潜在疾病风险、PPI 处方精简方法、社区处方精简实践、开展处方精简的困难进行综述,为促进社区PPI的长期合理使用提供参考。

关键词: 质子泵抑制剂, 合理用药, 处方精简, 全科医生, 社区医疗卫生

中图分类号:

荆冠宁, 李俊霞. 社区成人长期使用质子泵抑制剂的处方精简[J]. 临床荟萃, 2021, 36(6): 552-556.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.06.015

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I6/552

参考文献 43

[1]	Naunton M, Peterson GM, Deeks LS, et al. We have had a gutful: The need for deprescribing proton pump inhibitors[J]. J Clin Pharm Ther, 2018, 43(1):65-72. doi: 10.1111/jcpt.12613 pmid: 28895169
[2]	Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy[J]. Gastroenterology, 2017, 153(1):35-48. doi: 10.1053/j.gastro.2017.04.047 URL
[3]	Xie Y, Bowe B, Li T, et al. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans[J]. BMJ Open, 2017, 7(6):e015735.
[4]	Zeng W. A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China[J]. BMC Health Serv Res, 2013, 13:390. doi: 10.1186/1472-6963-13-390 URL
[5]	Othman F, Card TR, Crooks CJ. Proton pump inhibitor prescribing patterns in the UK: a primary care database study[J]. Pharmacoepidemiol Drug Saf, 2016, 25(9):1079-1087. doi: 10.1002/pds.v25.9 URL
[6]	Roux B, Sirois C, Simard M, et al. Potentially inappropriate medications in older adults: a population-based cohort study[J]. Fam Pract, 2020, 37(2):173-179.
[7]	Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care[J]. Postgrad Med J, 2007, 83(975):66-68. pmid: 17267683
[8]	Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting[J]. Am J Manag Care, 2010, 16(9):e228-234.
[9]	张拥军, 郭曙光, 方健, 等. 住院患者质子泵抑制剂使用合理性分析[J]. 中国药业, 2017, 26(21):82-84.
[10]	Savarino V, Dulbecco P, de Bortoli N, et al. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal[J]. Eur J Intern Med, 2017, 37:19-24. doi: 10.1016/j.ejim.2016.10.007 URL
[11]	广东省药学会. 预防性使用质子泵抑制剂及处方精简专家指导意见[J]. 今日药学, 2019, 29(8):505-514.
[12]	Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline[J].[J]Can Fam Physician, 2017, 63(5):354-364.
[13]	柏愚, 李延青, 任旭, 等. 应激性溃疡防治专家建议(2018版)[J]. 中华医学杂志, 2018, 98(42):3392-3395.
[14]	Kereiakes DJ, Yeh RW, Massaro JM, et al. DAPT score utility for risk prediction in patients with or without previous myocardial infarction[J]. J Am Coll Cardiol, 2016, 67(21):2492-2502. doi: 10.1016/j.jacc.2016.03.485 pmid: 27046159
[15]	Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications[J]. Am J Gastroenterol, 2009, 104(3):728-738.
[16]	Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease[J]. N Engl J Med, 2010, 363(20):1909-1917. doi: 10.1056/NEJMoa1007964 URL
[17]	Chan F, Wong V, Suen B, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial[J]. Lancet, 2007, 369(9573):1621-1626. doi: 10.1016/S0140-6736(07)60749-1 URL
[18]	程芮, 李鹏. 胃内镜黏膜下剥离术围术期指南[J]. 中国医刊, 2017, 52(12):12-24.
[19]	Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice From the American Gastroenterological Association[J]. Gastroenterology, 2017, 152(4):706. doi: S0016-5085(17)30091-4 pmid: 28257716
[20]	Strand DS, Kim D, Peura DA. 25 Years of proton pump inhibitors: a comprehensive review[J]. Gut Liver, 2017, 11(1):27-37. doi: 10.5009/gnl15502 URL
[21]	Xie Y, Bowe B, Yan Y, et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study[J]. BMJ, 2019, 365:1580.
[22]	Xie Y, Bowe B, Li T, et al. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury[J]. Kidney Int, 2017, 91(6):1482-1494. doi: 10.1016/j.kint.2016.12.021 URL
[23]	Lee HJ, Lee H, Oh SH, et al. Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients[J]. PLoS One, 2018, 13(9):e0203878. doi: 10.1371/journal.pone.0203878 URL
[24]	By the 2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults the 2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults[J]. J Am Geriatr Soc, 2019, 67(4):674-694. doi: 10.1111/jgs.2019.67.issue-4 URL
[25]	O'Mahony D. STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: origin and progress[J]. Expert Rev Clin Pharmacol, 2020, 13(1):15-22. doi: 10.1080/17512433.2020.1697676 URL
[26]	O'Mahony D, O'Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2[J]. Age Ageing, 2015, 44(2):213-218. doi: 10.1093/ageing/afu145 pmid: 25324330
[27]	Thompson W, F B. Deprescribing: what is it and what does the evidence tell us?[J]. Can J Hosp Pharm, 2013, 66(3):201-202. pmid: 23814291
[28]	Bytzer P. Deprescribing proton pump inhibitors: why, when and how[J]. Med J Aust, 2018, 209(10) :436-438. pmid: 30404592
[29]	Xiao Y, Zhang S, Dai N, et al. Phase Ⅲ, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis[J]. Gut, 2020, 69(2):224-230. doi: 10.1136/gutjnl-2019-318365 URL
[30]	Bayerdörffer E, Bigard MA, Weiss W, et al. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease[J]. BMC Gastroenterol, 2016, 16:48. doi: 10.1186/s12876-016-0448-x pmid: 27080034
[31]	2020年中国胃食管反流病专家共识[J]. 中华消化杂志, 2020, 40(10):649-663.
[32]	Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015[J]. J Gastroenterol, 2016, 51(8):751-767. doi: 10.1007/s00535-016-1227-8 URL
[33]	Walsh K, Kwan D, Marr P, et al. Deprescribing in a family health team: a study of chronic proton pump inhibitor use[J]. J Prim Health Care, 2016, 8(2):164-171. doi: 10.1071/HC15946 pmid: 27477559
[34]	Dharmarajan TS, Choi H, Hossain N, et al. Deprescribing as a clinical improvement focus[J]. J Am Med Dir Assoc, 2020, 21(3):355-360. doi: 10.1016/j.jamda.2019.08.031 URL
[35]	Coyle C, Symonds R, Allan J, et al. Sustained proton pump inhibitor deprescribing among dyspeptic patients in general practice: a return to self-management through a programme of education and alginate rescue therapy. A prospective interventional study[J]. BJGP Open, 2019, 3(3):bjgpopen19X101651.
[36]	Rieckert A, Becker A, Donner-Banzhof N, et al. Reduction of the long-term use of proton pump inhibitors by a patient-oriented electronic decision support tool (arriba-PPI): study protocol for a randomized controlled trial[J]. Trials, 2019, 20(1):636. doi: 10.1186/s13063-019-3728-2 pmid: 31752978
[37]	Odenthal DR, Philbrick AM, Harris IM. Successful deprescribing of unnecessary proton pump inhibitors in a primary care clinic[J]. J Am Pharm Assoc (2003), 2019, 60(1):100-104. doi: 10.1016/j.japh.2019.08.012 URL
[38]	Wilsdon TD, Hendrix I, Thynne TR, et al. Effectiveness of interventions to deprescribe inappropriate proton pump inhibitors in older adults[J]. Drugs Aging, 2017, 34(4):265-287. doi: 10.1007/s40266-017-0442-1 pmid: 28220380
[39]	张莎, 蒙龙, 杨佳丹, 等. 重庆市某社区老年慢性病患者对处方精简态度的调查研究[J]. 中国药房, 2018, 29(10):1408-1411.
[40]	Galazzi A, Lusignani M, Chiarelli MT, et al. Attitudes towards polypharmacy and medication withdrawal among older inpatients in Italy[J]. Int J Clin Pharm, 2016, 38(2):454-461. doi: 10.1007/s11096-016-0279-4 URL
[41]	Ikeji C, Williams A, Hennawi G, et al. Patient and provider perspectives on deprescribing proton pump inhibitors[J]. J Gerontol Nurs, 2019, 45(10):9-17.
[42]	Gnjidic D, Le Couteur DG, Kouladjian L, et al. Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes[J]. Clin Geriatr Med, 2012, 28(2):237-253. doi: 10.1016/j.cger.2012.01.006 URL
[43]	Farrell B, Richardson L, Raman-Wilms L, et al. Self-efficacy for deprescribing: a survey for health care professionals using evidence-based deprescribing guidelines[J]. Res Social Adm Pharm, 2018, 14(1):18-25. doi: 10.1016/j.sapharm.2017.01.003 URL

社区成人长期使用质子泵抑制剂的处方精简

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 43

相关文章 14

编辑推荐

Metrics

本文评价

[1]	黄业鸿, 刘改芳, 忻晨曦, 赵云红, 吴婧. 质子泵抑制剂大剂量二联与铋剂四联在幽门螺杆菌根除治疗中的疗效比较[J]. 临床荟萃, 2022, 37(3): 230-233.
[2]	刘双，赵东强. 失代偿期肝硬化治疗中存在的几个问题[J]. 临床荟萃, 2020, 35(7): 647-652.
[3]	丁钰，闫秀娥. 嗜酸性食管炎与胃食管反流病关系[J]. 临床荟萃, 2017, 32(1): 42-45.
[4]	刘改芳. 幽门螺杆菌与胃食管反流病[J]. 临床荟萃, 2017, 32(1): 33-36.
[5]	韩菲，张晓岚. 胃食管反流病的药物治疗[J]. 临床荟萃, 2017, 32(1): 17-21.
[6]	白研1，白文元2. 难治性胃食管反流病的识别与治疗进展[J]. 临床荟萃, 2017, 32(1): 9-12.
[7]	金哲;周宝民;王大勇;高荣华;赵德坤;刘桂芳;付景瑞. 泮托拉唑联合奥曲肽在消化性溃疡并上消化道出血的治疗应用[J]. 临床荟萃, 2014, 29(11): 1299-1301.
[8]	褚晓华;吴立梅. 156例药品不良反应报告分析[J]. 临床荟萃, 2011, 26(7): 626-627.
[9]	李荣富;李欣;吴姗珊;孙涛. 长期使用质子泵抑制剂对肠道菌群的影响[J]. 临床荟萃, 2011, 26(22): 1940-1943.
[10]	郭艺芳;金雅丽. 氯吡格雷联合质子泵抑制剂可增加再梗死的风险[J]. 临床荟萃, 2009, 24(14): 1212-0.
[11]	常智忠;辛燕;杨素征;马瑞凤;吴子彬;田勇;卜彦斌. 质子泵抑制剂治疗应激性溃疡疗效观察[J]. 临床荟萃, 2007, 22(10): 739-740.
[12]	张静;丁士刚;林三仁;周丽雅;张莉;李渊. 幽门螺杆菌根除治疗方案比较[J]. 临床荟萃, 2006, 21(22): 1600-1602.
[13]	耿直;张正安;姬海青. 雷贝拉唑治疗反流性食管炎42例观察[J]. 临床荟萃, 2004, 19(12): 702-703.
[14]	刘国节;李京爱. 66株细菌药敏分析[J]. 临床荟萃, 2002, 17(24): 0-0.